228 related articles for article (PubMed ID: 27930856)
1. 'ProtecTion' from overtreatment: does a randomized trial finally answer the key question in localized prostate cancer?
Wang LL; Wallis CJ; Sathianathen N; Lawrentschuk N; Murphy DG; Nam R; Moon D
BJU Int; 2017 Apr; 119(4):513-514. PubMed ID: 27930856
[No Abstract] [Full Text] [Related]
2. Prostate cancer: Time for active surveillance of intermediate-risk disease?
Ahmed HU
Nat Rev Urol; 2013 Jan; 10(1):6-8. PubMed ID: 23147924
[No Abstract] [Full Text] [Related]
3. Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid.
van Tol-Geerdink JJ; Willem Leer J; Weijerman PC; van Oort IM; Vergunst H; van Lin EN; Alfred Witjes J; Stalmeier PF
BJU Int; 2013 Apr; 111(4):564-73. PubMed ID: 22882966
[TBL] [Abstract][Full Text] [Related]
4. The ProtecT trial: what can we expect?
Roobol MJ; Bokhorst LP
Lancet Oncol; 2014 Sep; 15(10):1046-7. PubMed ID: 25163904
[No Abstract] [Full Text] [Related]
5. Clinical trials: ProtecT-ing against prostate cancer.
Stone L
Nat Rev Urol; 2014 Nov; 11(11):601. PubMed ID: 25201617
[No Abstract] [Full Text] [Related]
6. Surgery or radiation: what is the optimal management for locally advanced prostate cancer?
Fletcher SG; Theodorescu D
Can J Urol; 2005 Feb; 12 Suppl 1():58-61; discussion 101-2. PubMed ID: 15780168
[TBL] [Abstract][Full Text] [Related]
7. [Prostatectomy vs. "watchful waiting" in early prostate cancer].
Markun S
Praxis (Bern 1994); 2014 Jul; 103(15):909-10. PubMed ID: 25051936
[No Abstract] [Full Text] [Related]
8. Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer.
Liu J; Womble PR; Merdan S; Miller DC; Montie JE; Denton BT;
Urology; 2015 Nov; 86(5):901-5. PubMed ID: 26358397
[TBL] [Abstract][Full Text] [Related]
9. Re: Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
Ahmed HU; Emberton M
J Urol; 2008 Aug; 180(2):780-1; author reply 781-3. PubMed ID: 18555492
[No Abstract] [Full Text] [Related]
10. The presence of high-grade prostatic intraepithelial neoplasia or atypia on prostate biopsy does not adversely affect prostatectomy outcomes for patients otherwise eligible for active surveillance.
Pietzak EJ; Kabarriti AE; Mucksavage P; Bavaria T; Van Arsdalen K; Malkowicz SB; Wein AJ; Guzzo TJ
Urology; 2014 Dec; 84(6):1442-7. PubMed ID: 25288572
[TBL] [Abstract][Full Text] [Related]
11. Classification system: organ preserving treatment for prostate cancer.
Ward JF; Jones JS
Urology; 2010 Jun; 75(6):1258-60. PubMed ID: 20080292
[No Abstract] [Full Text] [Related]
12. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
Eggener SE; Scardino PT; Carroll PR; Zelefsky MJ; Sartor O; Hricak H; Wheeler TM; Fine SW; Trachtenberg J; Rubin MA; Ohori M; Kuroiwa K; Rossignol M; Abenhaim L;
J Urol; 2007 Dec; 178(6):2260-7. PubMed ID: 17936815
[TBL] [Abstract][Full Text] [Related]
13. Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance.
Weiner AB; Etzioni R; Eggener SE
Eur Urol; 2014 Oct; 66(4):611-2. PubMed ID: 24630416
[No Abstract] [Full Text] [Related]
14. Editorial comment on: tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Gallina A
Eur Urol; 2010 Apr; 57(4):639. PubMed ID: 19299073
[No Abstract] [Full Text] [Related]
15. Editorial comment on: tumor grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Yossepowitch O
Eur Urol; 2010 Apr; 57(4):639-40. PubMed ID: 19299071
[No Abstract] [Full Text] [Related]
16. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
17. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.
Seiler D; Randazzo M; Klotz L; Grobholz R; Baumgartner M; Isbarn H; Recker F; Kwiatkowski M
BJU Int; 2012 Jul; 110(2):195-200. PubMed ID: 22093744
[TBL] [Abstract][Full Text] [Related]
18. Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Ladjevardi S; Sandblom G; Berglund A; Varenhorst E
Eur Urol; 2010 Apr; 57(4):631-8. PubMed ID: 19299069
[TBL] [Abstract][Full Text] [Related]
19. Improving clinical prognostic stratification models for men with prostate cancer: a practical step closer to more individualized care without added costs.
Gnanapragasam VJ; Warren AY
BJU Int; 2017 Mar; 119(3):366-367. PubMed ID: 27873452
[No Abstract] [Full Text] [Related]
20. Management of early prostate cancer.
Horwich A; Parker CC; Huddart RA; Dearnaley DP
Ann Oncol; 2002; 13 Suppl 4():83-7. PubMed ID: 12401671
[No Abstract] [Full Text] [Related]
[Next] [New Search]
